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Abstract
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel virus of the family Coronaviridae. The virus causes
the infectious disease COVID-19. The biology of coronaviruses has been studied for many years. However, bioinformatics
tools designed explicitly for SARS-CoV-2 have only recently been developed as a rapid reaction to the need for fast detection,
understanding and treatment of COVID-19. To control the ongoing COVID-19 pandemic, it is of utmost importance to get
insight into the evolution and pathogenesis of the virus. In this review, we cover bioinformatics workflows and tools for the
routine detection of SARS-CoV-2 infection, the reliable analysis of sequencing data, the tracking of the COVID-19 pandemic
and evaluation of containment measures, the study of coronavirus evolution, the discovery of potential drug targets and
development of therapeutic strategies. For each tool, we briefly describe its use case and how it advances research
specifically for SARS-CoV-2. All tools are free to use and available online, either through web applications or public code
repositories. Contact: evbc@unj-jena.de
Key words: virus bioinformatics; SARS-CoV-2; sequencing; epidemiology; drug design; tools
Introduction
On 31 December 2019, the Wuhan Municipal Health Commission
reported several cases of pneumonia in Wuhan (China) to
the World Health Organization (https://www.who.int/csr/don/
05-january-2020-pneumonia-of-unkown-cause-china/en/). The
cause of these cases was a previously unknown coronavirus,
now known as severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), which can manifest itself in the disease named
COVID-19. At the time of writing (22 July 2020), nearly 15
million cases were reported worldwide, with over 600 000
deaths (https://www.who.int/docs/default-source/coronaviruse/
situation-reports/20200722-covid-19-sitrep-184.pdf). The group
of Coronaviridae includes viruses with very long RNA genomes
up to 33 000 nucleotides. SARS-CoV-2 belongs to the Sarbecovirus
subgenus (genus: Betacoronavirus) and has a genome of approx-
imately 30 000 nucleotides [119]. In line with other members of
Coronaviridae, SARS-CoV-2 has four main structural proteins:
spike (S), envelope (E), membrane (M) and nucleocapsid (N).
Further, several nonstructural proteins are encoded in the pp1a
and pp1ab polyproteins, which are essential for viral replication
[119]. SARS-CoV-2 seems to use the human receptor ACE2 as its
main entry [34], which has been observed for other Sarbecoviruses
as well [32, 55]. The binding domains for ACE2 are located on the
spike proteins, which further contain a novel furin cleavage
site, associated with increased pathogenicity and transmission
potential [46, 66, 95, 112].
Although SARS-CoV-2 has a lower mutation rate than most
RNA viruses, mutations certainly accumulate and result in
genomic diversity both between and within individual infected
patients. Genetic heterogeneity enables viral adaptation to
different hosts and different environments within hosts and
is often associated with disease progression, drug resistance
and treatment outcome.
In light of the COVID-19 pandemic, there has been a rapid
increase in SARS-CoV-2-related research. It will be critical to
get insight into the evolution and pathogenesis of the virus in
order to control this pandemic. Researchers around the world
are investigating SARS-CoV-2 sequence evolution on genome
and protein level, tracking the pandemic using phylodynamic
and epidemiological models and examining potential drug
targets. Laboratories are sharing SARS-CoV-2-related data with
unprecedented speed. In light of this sheer amount of data, many
fundamental questions in SARS-CoV-2 research can only be
tackled with the help of bioinformaticians. Adequate analysis of
these data has the potential to boost discovery and inform both
fundamental and applied science, in addition to public health
initiatives.
SARS-CoV-2 is an entirely novel pathogen, and in light of
the pandemic requiring a swift response to research and pub-
lic health-related questions, the natural first approach is to
repurpose existing methods and resources. Simultaneously, the
outbreak has had a huge impact on virus bioinformatics tools
that have been developed recently and it is important to under-
stand which tools are applicable to coronaviruses and which
have been customized to address research questions related to
SARS-CoV-2.
In this review, we cover bioinformatics workflows and
tools (see Table 1) starting with the routine detection of SARS-
CoV-2 infection, the reliable analysis of sequencing data, the
tracking of the COVID-19 pandemic, the study of coronavirus
evolution, up to the detection of potential drug targets and
development of therapeutic strategies. All tools have either been
developed explicitly for SARS-CoV-2 research, have been
extended or adapted to coronaviruses or are of particular impor-
tance to study SARS-CoV-2 epidemiology and pathogenesis.
Detection and annotation
The routine detection method for SARS-CoV-2 is a real-time
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(qRT-PCR). The test is based on the detection of two nucleotide
sequences: the virus envelope (E) gene and the gene for the RNA-
dependent RNA polymerase (RdRp) [11]. Specificity (exclusion
of false positives) and sensitivity (exclusion of false negatives)
are two of the most important quality criteria for the validity
of diagnostic tests. To ensure unique identification of SARS-
CoV-2 and avoid false-negative and false-positive detection, the
computation of SARS-CoV-2-specific primers is required. A new
set of primers might be required if the specificity or sensitivity
of the qRT-PCR test changes due to mutations in the SARS-CoV-2
genome or related coronavirus genomes (see PriSeT).
Besides qRT-PCR, genome analysis plays a crucial role in
public health responses, including epidemiological efforts to
track and contain the outbreak (see Tracking, epidemiology and
evolution). The genome sequence of SARS-CoV-2 was rapidly
determined and shared on GenBank (MN908947.3). It is anno-
tated based on sequence similarity to other coronaviruses. Next-
generation sequencing (NGS) can be used to assess the genomic
diversity of the virus. Regular sequencing from clinical cases is
useful, for example, to monitor for mutations that might affect
the qRT-PCR test (see CoVPipe, V-Pipe). To reliably derive intra-
host diversity estimates from deep sequencing data is challeng-
ing since most variants occur at low frequencies in the virus
population and amplification and sequencing errors confound
their detection. Multiple related viral strains (haplotypes) are
hard to resolve but may be critical for the choice of therapy (see
Haploflow, V-Pipe).
The SARS-CoV-2 nanopore sequencing protocol has been
developed and optimized by the ARTIC network [78], which has
extensive experience and expertise in deploying this technol-
ogy in the sequencing and surveillance of outbreaks, including
Zika and Ebola [79]. Nanopore sequencing is used to quickly
generate high-accuracy genomes of SARS-CoV-2 and track both
transmission of COVID-19 and viral evolution over time (see
poreCov).
In addition to amplicon-based sequencing approaches,
metagenomic/-transcriptomic sequencing offers the ability to
identify the primary pathogen and additional infections that
may be present [70]. It can be used to identify coronaviruses
in clinical and environmental samples, e.g. from human
Bronchoalveolar lavage fluid (see VIRify). SARS-CoV-2 genomic
traces in human faecal metagenomes from before the pandemic
support the hypothesis of a possible presence of a most recent
common ancestor of SARS-CoV-2 in the human population
before the outbreak of the current pandemic, possibly in an
inactive non-virulent form [81]. Further, metagenomics helps to
check sequence divergence as the virus could undergo mutation
and recombination with other human coronaviruses.
To help fight the COVID-19 pandemic, it is essential to make
high-quality SARS-CoV-2 genome sequence data and metadata
available through open databases either via a data-access agree-
ment (e.g. GISAID, https://www.gisaid.org/) or without restric-
tions (e.g. GenBank, https://submit.ncbi.nlm.nih.gov/sarscov2/).
On GISAID (Global Initiative on Sharing All Influenza Data), lab-
oratories around the world have shared viral genome sequence
data with unprecedented speed (>71 000 SARS-CoV-2 genomic
sequences on 23 July 2020). We encourage researchers to sub-
mit genome sequences to public databases that do not impose
limitations on the sharing and use of the genomic sequences.
NCBI offers a new streamlined submission process for SARS-
CoV-2 data (https://ncbiinsights.ncbi.nlm.nih.gov/2020/04/09/sa
rs-cov2-data-streamlined-submission-rapid-turnaround/).
Several bioinformatics tools have been developed for the
detection and annotation of SARS-CoV-2 genomes (see VADR,
V-Pipe, VIRify, VBRC tools, VIRULIGN). Comparative genomics
helps to detect differences to other coronaviruses, e.g. SARS-
CoV-1, which might affect the functionality and pathogenesis of
the virus.
Aside from coding sequences and proteins, the identification
of conserved functional RNA secondary structures (see Rfam)
is essential to understanding the molecular mechanisms of the
virus life cycle [63, 91]. Coronaviruses are known to have highly
structured, conserved untranslated regions, which harbour cis-
regulatory RNA secondary structure, controlling viral replication
and translation, and even small changes in these structures
reduce the viral load drastically [25, 61, 120].
Studying viral genomic diversity and the evolution of coding
and non-coding sequences (see UniProt, Pfam, Rfam) is impor-
tant for a better understanding of the evolution and epidemi-
ology of SARS-CoV-2 (see Tracking, epidemiology and evolution)
and the molecular mechanisms underlying COVID-19 pathogen-
esis (see Drug design).
PriSeT: Primer Search Tool
PriSeT [35] is a software tool that identifies chemically suitable
PCR primers in a reference data set. The reference data set can
be a FASTA file of complete genomes or a set of short regions. It
is optimized for metabarcoding experiments where species are
identified from an environmental sample based on a barcode—
a relatively short region from the genome. The most frequently
applied type of PCR for such experiments is the paired-end PCR—
two different primer sequences are chosen to be complementary
to the template and located within an offset range. The region in
between is the amplicon or barcode and will be matched against
the reference database to resolve operational taxonomic units to
organisms. The precise constraint ranges can be adjusted by the
user.
SARS-CoV-2 tests typically use mucus from the nose or throat
that undergo a metabarcoding analysis. For DNA amplification
RT-PCR is applied, which has more stringent requirements for
the primer sequences and the DNA product length. Figure 1
shows the approximate locations of in silico transcripts of 114
primer pairs computed by PriSeT on 19 SARS-CoV-2 genomes
with recommended RT-PCR settings [35]. The corresponding
primer pairs have no co-occurrences in other coronaviruses.
An additional online search on NCBI’s GenBank confirmed
that they also have no matches in any other sequences
that are not assigned to SARS-CoV-2. A list of SARS-CoV-2-
specific primer pairs computed on 19 SARS-CoV-2 genomes is
available on ResearchGate (https://www.researchgate.net/publi
cation/340418344_Primer_pairs_for_detection_of_SARS-CoV-2_
via_RT-PCR).
The computation of SARS-CoV-2-specific primers will help to
design RT-PCR tests, since the resulting barcodes serve as unique
identifiers for SARS-CoV-2 and avoid false-negative and false-
positive identifications.
PriSeT is hosted on GitHub under the GNU General Public
License v3.0 (GPLv3): https://github.com/mariehoffmann/PriSeT.
CoVPipe: amplicon-based genome reconstruction
CoVPipe is a highly optimized and fully automated workflow
for the reference-based reconstruction of SARS-CoV-2 genomes
based on next-generation amplicon sequencing data using
CleanPlex
®
SARS-CoV-2 panels (Paragon Genomics, Hayward,
CA, USA) from swab samples. The pipeline applies read
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Figure 1. SARS-CoV-2-specific primers computed with PriSeT. Approximate amplicon locations of de novo computed primer pairs for SARS-CoV-2 with no co-occurrences
in other genomes in GenBank (on 3 April 2020).
primer sequences or primer hybrids as well as Illumina adapters
and low-quality bases. The processed reads are then aligned to
a given reference sequence using BWA-MEM [54]. Resulting BAM
files are evaluated to report mapping quality measurements like
coverage, read depth and insert size (bedtools v2.27 and samtools
v1.3). Variants are called using GATK (v4.1) [64] and filtered
following best practices of GATK. Finally, different consensus
sequences can be created using different masking methods.
Additionally, detailed information such as coverage, genomic
localization and effect on respective gene products are reported
for each variant site.
The pipeline is designed for reproducibility and scalability
in order to ensure reliable and fast data analysis of SARS-CoV-2
data. The workflow itself is implemented using Snakemake [48],
which provides advanced job balancing and input/output control
mechanisms, and uses conda [28] to provide well-defined and
harmonized software environments.
CoVPipe is available via GitLab under GPLv3: https://gitlab.
com/RKIBioinformaticsPipelines/ ncov_minipipe.
poreCov: rapid sample analysis for nanopore
sequencing
Nanopore workflows were previously used in other outbreak
situations, e.g. Zika, Ebola, Yellow Fever, Swine Flu, and can
deliver a consensus viral genome after approximately 7 hours
(https://nanoporetech.com/about-us/news/novel-coronaviru
s-covid-19-information-and-updates). The ARTIC network
provides all the necessary information, tools and protocols
to assist groups in sequencing the coronavirus via nanopore
sequencing (https://artic.network/ncov-2019). These protocols
utilize a multiplex PCR approach to amplify the virus directly
from clinical samples, followed by sequencing and bioinformatic
steps to assemble the data (https://artic.network/ncov-2019/nco
v2019-bioinformatics-sop.html). Due to the small viral genome,
up to 24 samples can be sequenced at the same time. Rapid
sample analysis is, therefore, of particular interest.
The workflow poreCov is implemented in nextflow [100]
for full parallelization of the workload and stable sample
processing (see Figure 2). poreCov generates all necessary results
and information before scientists continue to analyze their
genomes or make them public on, e.g. GISAID or ENA / NCBI.
The workflow carries out all necessary steps from basecalling
to assembly depending on the user input, followed by lineage
prediction of each genome using Pangolin (see below). Fur-
thermore, read coverage plots are provided for each genome
to assess the amplification quality of the multiplex PCR. In
addition, poreCov includes a quick-time, tree-based analysis of
the inputs against reference sequences using augur (https://gi
thub.com/nextstrain/augur) and toytree (https://github.com/ea
ton-lab/toytree) for visualization. poreCov supports scientists
in their SARS-CoV-2 research by reducing the time-consuming
bioinformatic bottlenecks in processing dozens of SARS-CoV-2
sequencing runs.
All tools are provided via ‘containers’ (pre-build and stored
on docker hub) to generate a reproducible workflow in various
working environments. poreCov is available on GitHub under
GPLv3: https://github.com/replikation/poreCov.
VADR: SARS-CoV-2 genome annotation and validation
VADR validates and annotates viral sequences based on models
built from reference sequences [85]. Coronavirus models,
based on NCBI RefSeq [73] entries, including one for SARS-
CoV-2 (NC_045512.2), are available for analyzing coronavirus
sequences. VADR computes an alignment of each incoming
sequence against the RefSeq and uses it to map the RefSeq
features, which include protein coding sequences (CDS), genes,
mature peptides (mat_peptide) and structural RNA (stem_loop)
features. The ORF1ab polyprotein CDS involves a programmed
ribosomal frameshift, which VADR is capable of properly
annotating. The tool identifies and outputs information about
more than 40 types of problems with sequences, such as
early stop codons in CDS, and has been in use by GenBank
for screening and annotating incoming SARS-CoV-2 sequence
submissions since March 2020. VADR (v1.1) includes heuristics
for accelerating annotation and for dealing with stretches of
ambiguous N nucleotides, that were specifically added for
SARS-CoV-2 analysis.
VADR helps advance SARS-CoV-2 research by standardizing
the annotation of SARS-CoV-2 sequences deposited in GenBank
and other databases and by allowing researchers to fully anno-
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Figure 2. Simplified overview of the poreCov workflow. The individual workflow steps (blue) are executed automatically depending on the input (yellow). Instead of
using raw nanopore fast5 files, fastq files or complete SARS-CoV-2 genomes can be used as an alternative input. If reference genomes and location/times are added, a
time tree is additionally constructed.
VADR is available via GitHub (public domain): https://githu
b.com/nawrockie/vadr, including specific instructions for use
on SARS-CoV-2 sequences (https://github.com/nawrockie/vadr/
wiki/Coronavirus-annotation).
V-Pipe: calling single-nucleotide variants and viral
haplotypes
V-pipe [77] is a bioinformatics pipeline that integrates various
computational tools for the analysis of viral high-throughput
sequencing data. It supports the reproducible end-to-end analy-
sis of intra-host NGS data, including quality control, read map-
ping and alignment and inference of viral genomic diversity on
the level of both single-nucleotide variants (SNVs) and long-
range viral haplotypes. V-pipe uses the workflow management
system Snakemake [48] to organize the order of required compu-
tational steps, and it supports cluster computing environments.
It is easy to use from the command line, and conda [28] envi-
ronments facilitate installation. V-pipe’s modular architecture
allows users to design their pipelines and developers to test their
tools in a defined environment, enabling best practices for viral
bioinformatics.
A recent release of V-pipe addresses specifically the analysis
of SARS-CoV-2 sequencing data. It uses the strain NC_045512
(GenBank: MN908947.3) as the default for read mapping and
reporting of genetic variants, and it includes several improve-
ments, for example, for calling single-nucleotide variants. Also,
V-pipe can generate a comprehensive and intuitive visualization
of the detected genomic variation in the context of various
annotations of the SARS-CoV-2 genome. This summary of the
output can help to generate diagnostic reports based on viral
genomic data.
V-pipe is an SIB resource (https://www.sib.swiss/research-
infrastructure/database-software-tools/sib-resources) and avail-
able via GitHub under the Apache License 2.0 (APLv2): https://
github.com/cbg-ethz/V-pipe. Users are supported through the
website (https://cbg-ethz.github.io/V-pipe/), tutorials, videos, a
mailing list and the dedicated wiki pages of the GitHub repos-
itory.
Haploflow: Multi-strain aware de novo assembly
Viral infections often include multiple related viral strains
[113], either due to co-infection or within-host evolution. These
strains - haplotypes - may vary in phenotype due to certain,
strain-specific genetic properties [51]. It is not entirely clear yet
whether SARS-CoV-2 has a tendency for multiple infections,
though there are indications that co-infections with other
Coronaviruses do occur [59]. Most assemblers struggle with
resolving complete viral haplotypes, even though these may be
critical for the choice of therapy. Haploflow is a novel, de Bruijn
graph-based assembler for the de novo, strain-resolved assembly
of viruses that is able to rapidly resolve differences up to a base-
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Figure 3. Sequence reads from a human lung metatranscriptome (sample accession: SAMN13922059) were first quality-filtered using TrimGalore v0.6.0 and
subsequently assembled using MEGAHIT v1.1.3 [53] with default parameters. The resulting metatranscriptome assembly was processed through the VIRify pipeline.
Based on the hits against the ViPhOG database, a 29 kb contig was classified as Coronaviridae. Functional protein domain annotations (inner track) were assigned by an
hmmsearch v3.1b2 against coronavirus models in Pfam. The image was created with circlize [29] and polished with Inkscape.
SARS-CoV-2 research by enabling the detection and full-length
reconstruction of SARS-CoV-2 multi-strain infections.
Haploflow is available on GitHub under APLv2: https://github.
com/hzi-bifo/Haploflow
VIRify: Annotation of viruses in meta-omic data
VIRify is a recently developed generic pipeline for the detection,
annotation and taxonomic classification of viral and phage con-
tigs in metagenomic and metatranscriptomic assemblies. This
pipeline is part of the repertoire of analysis services offered by
MGnify [69]. VIRify’s taxonomic classification relies on the detec-
tion of taxon-specific profile hidden Markov models (HMMs),
built upon a set of 22,014 orthologous protein domains and
referred to as ViPhOGs. Included in this profile HMM database
are 139 models that serve as specific markers for taxa within
the Coronaviridae family.
Here, we show the applicability of VIRify on the assembly of
a metatranscriptomic dataset from a human Bronchoalveolar
lavage fluid. Within this assembly, a 29 kb contig was clas-
sified by VIRify as belonging to the Coronaviridae family (see
Figure 3). This shows the utility of the VIRify pipeline, used in
isolation from MGnify, for studying coronaviruses in the human
respiratory microbiome.
VIRify can be used for the identification of coronaviruses
in clinical and environmental samples. Due to the intrinsic
differences between metatranscriptomes and metagenomes,
additional considerations regarding quality control, assembly,
post-processing and classification have to be kept in mind (for
details, see https://github.com/EBI-Metagenomics/emg-viral-
pipeline).
VIRify is available via GitHub under APLv2: https://github.
com/EBI-Metagenomics/emg-viral-pipeline.
Genome analysis tools by VBRC
The Viral Bioinformatics Research Centre (VBRC) is a mature
resource built specifically for virologists to facilitate the
comparative analysis of viral genomes. Within VBRC, a MySQL
database created from GenBank files supports numerous
analysis tools. The curated database is accessed through Virus
Orthologous Clusters [16], a powerful, but easy-to-use database
GUI. Base-By-Base [9, 33, 102] is a tool for generating, visualizing
and editing multiple sequence alignments. It can compare
genomes, genes or proteins via alignments and plots. Users
can add comments to sequences and save alignments to a
local computer. Viral Genome Organizer [105] visualizes and
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Figure 4. A region of recombination in coronavirus genomes at three levels of resolution in Base-By-Base. Top panel: aligned genomes; blue boxes show differences
compared to top sequence in alignment. Middle panel: summary view showing differences and indels compared top sequence. Bottom panel: similarity plot comparing
five genomes.
viral genomes. The tool allows the user to export protein or DNA
sequences and can display START/STOP codons for 6-frames as
well as open reading frames and other user-defined results. If
genomes are loaded from the database, it can display shared
orthologs. Genome Annotation Transfer Utility [98] is a tool
for annotating genomes using information from a reference
genome. It provides for interactive annotation, automatically
annotating genes that are very similar to the reference virus but
leaving others for a human decision.
The VBRC was developed for dsDNA viruses but has been
adapted for coronaviruses. SARS-CoV-2 and closely related
viruses have been added to the database. VBRC tools will
help to visualize differences between coronavirus sequences
at different levels of resolution (see Figure 4).
VBRC is available via https://www.4virology.net; all tools are
published under GPLv3.
VIRULIGN: Codon-correct multiple sequence
alignments
VIRULIGN was developed for fast, codon-correct multiple
sequence alignment and annotation of virus genomes, guided by
a reference sequence [58]. A codon-aware alignment is essential
for studying the evolution of coding nucleotide sequences to aid
vaccine and antiviral development [12], to understand the emer-
gence of drug resistance [72] and to quantify epidemiological
potential [76]. [99] have shown that a representative and curated
annotation of open reading frames and proteins is essential to
study emerging pathogens. To this end, a SARS-CoV-2 reference
sequence and genome annotation have been added to VIRULIGN,
based on the first available genome sequence [119], covering all
reading frames and proteins.
VIRULIGN is easy to install, enabling scientists to perform
large-scale analyses on their local computational infrastructure.
VIRULIGN is particularly well suited to study the rapidly growing
number of SARS-CoV-2 genomes made available [80], due to its
efficient alignment algorithm that has linear computational
complexity with respect to the number of sequences studied.
Furthermore, VIRULIGN’s flexible output formats (e.g. CSV file
with headers corresponding to the genome annotation) facilitate
its integration into analysis workflows, lowering the threshold
for scientists to deliver advanced bioinformatics pipelines [13,
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Table 2. Rfam version 14.2 matches to the SARS-CoV-2 RefSeq entry NC_045512.2
RefSeq coordinates Rfam
accession
Rfam ID Rfam description Comment
NC_045512.2/1-299 RF03120 Sarbecovirus-5UTR Sarbecovirus 5’ UTR See Rfam family RF03117 for
Betacoronavirus 5’ UTR.




NC_045512.2/29,536-29,870 RF03125 Sarbecovirus-3UTR Sarbecovirus 3’ UTR See Rfam family RF03122 for
Betacoronavirus 3’ UTR.
NC_045512.2/29,603-29,662 RF00164 Corona_pk3 Coronavirus 3’ UTR
pseudoknot
The family annotates the
pseudoknot found in the 3’ UTR
(RF03120).
NC_045512.2/29,727-29,769 RF00165 s2m Coronavirus 3’
stem-loop II-like
motif (s2m)
The family is a subset of the 3’ UTR
model (RF03120) that corresponds to
the PDB:1XJR 3D structure from
SARS-CoV-1.
VIRULIGN is available via GitHub under the the GNU Gen-
eral Public License v2.0 (GPLv2): https://github.com/rega-cev/
virulign.
Rfam COVID-19 resources: coronavirus-specific RNA
families
Rfam [40] is a database of RNA families that hosts curated mul-
tiple sequence alignments and covariance models. To facilitate
the analysis of Coronavirus sequences, Rfam produced a special
release 14.2 with ten new families representing the entire 5’
and 3’ untranslated regions (UTRs) from Alpha-, Beta-, Gamma-
and Deltacoronaviruses. A specialized set of Sarbecovirus models
is also provided, which includes SARS-CoV-1 and SARS-CoV-2
sequences. The families are based on a set of high-quality whole
genome alignments that have been reviewed by expert virolo-
gists. In addition, Rfam now contains a revised set of non-UTR
Coronavirus structured RNAs, such as the frameshift stimulating
element, s2m RNA, and the 3’ UTR pseudoknot.
The new Rfam families can be used in conjunction with
the Infernal software [71] to annotate structured RNAs in Coro-
navirus sequences and predict their secondary structure (see
Figure 5). Table 2 shows the results for the SARS-CoV-2 Ref-
Seq entry (NC_045512.2). In addition, the online Rfam sequence
search enables users to scan genomic sequences and find the
RNA elements.
The Coronavirus Rfam families are available freely available
under the Creative Commons Zero (CC0) licence at https://rfam.
org/covid-19.
UniProt COVID-19 protein portal: rapid access to
protein information
UniProt [104] has recognized the urgency of annotating and
providing access to the latest information on proteins rele-
vant to the disease for both the virus and human host. In
response, the COVID-19 UniProt portal provides early pre-release
access to (i) SARS-CoV-2 annotated protein sequences, (ii) closest
SARS proteins from SARS 2003, (iii) human proteins relevant
to the biology of viral infection, like receptors and enzymes,
(iv) ProtVista [115] visualization of sequence features for each
protein, (v) links to sequence analysis tools, (vi) access to collated
community-contributed publications relevant to COVID-19, as
well as (vii) links to relevant resources.
The COVID-19 portal enables community crowdsourcing of
publications via the “Add a publication” feature within any entry.
Thus, the community can assist in associating new or missing
publications to relevant UniProt entries. ORCID is used as a
mechanism to validate user credentials as well as recognition for
contribution. Ten publication submissions have been received
so far, contributing to our understanding of the virus biology.
The COVID-19 UniProt portal advances SARS-CoV-2 research by
providing latest knowledge on proteins relevant to the disease
for both the virus and human host.
The COVID-19 UniProt portal is available under the Creative
Commons Attribution License (CC BY 4.0) via https://covid-19.
uniprot.org/. UniProt also hosted webinars to describe the por-
tal (https://www.youtube.com/watch?v=EY69TjnVhRs) and pub-
lication submission system (https://www.youtube.com/watch?
v=sOPZHLtQK9k).
Pfam protein families database
The Pfam protein families database is widely used in the field
of molecular biology for large-scale functional annotation of
proteins [17]. The latest release of Pfam, version 33.1, contains
an updated set of models that comprehensively cover the pro-
teins encoded by SARS-CoV-2 (see Table 3). The only SARS-CoV-
2 protein that lacks a match is Orf10, a small putative protein
found at the 3’-end of the SARS-CoV-2 genome, which appears
to lack similarity to any other sequence in UniProtKB (https://
covid-19.uniprot.org/). The Pfam profile hidden Markov model
(HMM) library in combination with the HMMER software [15]
facilitates rapid search and annotation of coronaviruses and can
be used to generate multiple sequence alignments that allow the
identification of mutations and clusters of related sequences,
particularly useful for outbreak tracking and studying the evo-
lution of coronaviruses.
The Pfam HMM library can be downloaded from https://pfa
m.xfam.org and can be used in combination with pfam_scan to
perform Pfam analysis locally. Multiple sequence alignments of
matches can be generated using hmmalign (http://hmmer.org/).
Precalculated matches and alignments are available from the
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Figure 5. SARS-CoV-2 Rfam secondary structure predictions. The sequence is based on the NC_045512.2 RefSeq entry displayed with the wuhCor1 UCSC Genome
Browser alongside the NCBI Genes track.
Pfam_SARS-CoV-2_2.0/). Pfam is freely available under the Cre-
ative Commons Zero (CC0) licence.
Tracking, epidemiology and evolution
As there is no universal approach for classifying a virus species’
genetic diversity, the phylogenetic clades are referred to by dif-
ferent terms, such as ‘subtypes’, ‘genotypes’ or ‘groups’. How-
ever, phylogenetic assignment is important for studies on virus
epidemiology, evolution and pathogenesis (see Covidex, Pan-
golin). Thus, a nomenclature system for naming the growing
number of phylogenetic lineages that make up the popula-
tion diversity of SARS-CoV-2 is needed. [80] have described a
lineage nomenclature for SARS-CoV-2 that arises from a set
of fundamental evolutionary, phylogenetic and epidemiological
principles.
Phylodynamic models may aid in dating the origins of pan-
demics, provide insights into epidemiological parameters, e.g.
R0 [110], or help determine the effectiveness of virus control
efforts (see BEAST 2, phylogeographic reconstruction). Phylody-
namic analyses aim to conclude epidemiological processes from
viral phylogenies, at the most basic level by comparing genetic
relatedness to geographic relatedness.
Mathematical epidemiological models project the progress of
the pandemic to show the likely outcome and help inform pub-
lic health interventions (see COPASI, COVIDSIM). Such models
help with analysing the effects of contact reduction measures
or other interventions, forecasting hospital resource usage and
guiding political decision-making.
As the pandemic progresses, SARS-CoV-2 is naturally accu-
mulating mutations. On average, the observed changes would be
expected to have no or minimal consequence for virus biology.
However, tracking these changes (see CoV-GLUE, PoSeiDon) will
help us better understand the pandemic and could help improve
the effectiveness of antiviral drugs and vaccines, both pharma-
ceutical prevention measures that will be crucial to control the
COVID-19 pandemic [38, 101].
Covidex: alignment-free subtyping using machine
learning
Viral subtypes or clades represent clusters among isolates from
the global population of a defined species. Subtypification is rel-
evant for studies on virus epidemiology, evolution and pathogen-
esis. Most subtype classification methods require the alignment
of the input data against a set of pre-defined subtype reference
sequences. These methods can be computationally expensive,
particularly for long sequences such as SARS-CoV-2 (≈30 kb per
genome). To tackle this problem, machine learning tools may be
used for virus subtyping [92]. Covidex was developed as an open-
source alignment-free machine learning subtyping tool. It is a
shiny app [10] that allows fast and accurate (out-of-bag error rate
< 1.5 %) classification of viral genomes in pre-defined clusters
(see Figure 6). For SARS-CoV-2, the default uploaded model is
based on Nextstrain [31] and GISAID data [18]. Alternatively,
user-uploaded models can be used. Covidex is based on a fast
implementation of random forest trained over a k-mer database
[7, 118]. By training the classification algorithms over k-mer
frequency vectors, Covidex substantially reduces computational
and time requirements and can classify hundreds of SARS-CoV-
2 genomes in seconds. Thus, in the context of the current global
pandemic where the number of available SARS-CoV-2 genomes
is growing exponentially, SARS-CoV-2 research can benefit from
this specific tool designed to reduce the time needed in data
analysis significantly.
Covidex is available via SourceForge under GPLv3: https://sou








obert Koch-Institut user on 09 August 2021
654 F. Hufsky et al.
Figure 6. Overview of Covidex for viral subtyping analysis. Left: The user is expected to load a sequence file and to select the model that will be applied for classification.
Models may be selected from the default list or uploaded by the user. Right: The program output (table and plots).
Pangolin: Phylogenetic Assignment of Named Global
Outbreak LINeages
Pangolin assigns a global lineage to query SARS-CoV-2 genomes
by estimating the most likely placement within a phylogenetic
tree of representative sequences from all currently defined
global SARS-CoV-2 lineages based on the lineage nomenclature
proposed by [80]. It is easily scalable so that it can be run on
either thousands or a handful of sequences. Internally, pangolin
runs mafft [42] and iqtree [67, 68], providing a guide tree and
alignment to keep analysis overhead relatively lightweight.
Pangolin has many applications, including frontline hospital
use and local and global surveillance. For example, in hospitals
sequencing SARS-CoV-2 samples, it could be used to rule out
within-hospital transmission, informing infection control mea-
sures. It can also be used for surveillance purposes, summa-
rizing which lineages are present in an area of interest. The
web-application also connects with Microreact (microreact.org)
displaying query sequences in the context of the global lineages
worldwide. pangolin is used as part of COG-UK’s (https://www.
cogconsortium.uk/) data processing pipeline to assign lineages
to UK sequences. Further, users can define their own finer-scale
lineages, for instance within-country lineages, and provide their
own guide tree and alignment.
Pangolin makes it easy to get useful information out of viral
genome sequencing in real-time and can assist in identifying
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Pangolin is available via GitHub under GPLv3: https://github.
com/hCoV-2019/pangolin/ and as web application via https://pa
ngolin.cog-uk.io/.
BEAST 2: phylodynamics based on Bayesian inference
Important evolutionary and epidemiological questions regarding
SARS-CoV-2 can be addressed using Bayesian phylodynamic
inference [27], which allows the adequate combination of
evidence from multiple independent sources of data, such as
genome sequences, sampling dates and geographic locations.
BEAST 2 [6] is an advanced computational software framework
that enables sophisticated Bayesian analyses utilizing a range
of phylodynamic packages, e.g. [14, 45, 50, 93, 107, 108, 111]. The
phylogenetic history (the tree) can be inferred simultaneously
with evolutionary and epidemiological parameters, such that the
uncertainty from all aspects of the joined model is accounted
for and reflected in the results. Phylodynamic analysis of SARS-
CoV-2 is crucial in understanding (i) SARS-CoV-2 evolutionary
dynamics, particularly through estimation of the evolutionary
rate at which mutations get fixated in the viral genome, (ii)
the temporal origin of a selection of COVID-19 cases as an
approximation of the time at which a sub-epidemic emerged,
(iii) the geographical origin of sub-epidemics, (iv) SARS-CoV-2
transmission dynamics, e.g. through direct estimation of the
effective reproduction number Re and its changes through time,
and (v) the proportion of undetected COVID-19 cases. Indeed,
due to the evolutionary and epidemiological processes occurring
on the same time scale, the diversity in the viral genome sheds
light on between-host transmission dynamics - making Bayesian
phylodynamic analysis of SARS-CoV-2 a crucial complement to
classical epidemiological methods.
BEAST 2 is available via https://www.beast2.org/ under the
GNU Lesser General Public License (LGPL).
Phylogeographic reconstruction using air
transportation data
Phylogeographic methods combine genomic data with the sam-
pling locations of viral isolates and models of spread, e.g. using
air travel or local diffusion, to reconstruct the putative spread
paths and outbreak origins of rapidly evolving pathogens. [82]
published a method that infers locations for internal nodes of a
phylogenetic tree using a parsimonious reconstruction together
with effective distances, as defined by [8]. Effective distances
are calculated based on passenger flows between airports. A
strong connection between two airports is represented by a
small distance. Using these distances as a cost matrix, the
parsimonious reconstruction identifies ancestral locations for
internal nodes of the tree that minimize the distances along
the phylogeny. This method allows rapid inferences of spread
paths on a fine-grained geographical scale [82]. Reconstruction
using effective distances infers phylogeographic spread more
accurately than reconstruction using geographic distances
or Bayesian reconstructions that do not use any distance
information.
Phylogeographic reconstruction using air transportation data
can be used to study the global spread of the SARS-CoV-2 pan-
demic, especially in the early phases when air travel still sub-
stantially contributed to the spread of the virus. The method is
currently adapted to consider both air travel and local movement
data within countries during inference to reflect the changing
worldwide movements in different phases of the pandemic.
The code is included in the GitHub repository for [82] under
APLv2: https://github.com/hzi-bifo/Phylogeography_Paper
COPASI: modeling SARS-CoV-2 dynamics with
differential equations
COPASI is a dynamics simulator, originally focused on chemical
and biochemical reaction networks [37]. However, it is by now
also widely applied to other fields, including epidemiology. It
allows simulating models with the traditional differential equa-
tion approach that represents populations as continua, as well
as with a stochastic kinetics approach which considers pop-
ulations are composed of individuals. COPASI has a common
model representation for both these approaches, which allows
switching between them with ease. Additionally, one can add
arbitrary discrete events to models. This software is equipped
with several algorithms that provide comprehensive analyses
of models, and it has support for parameter estimation using
a series of optimization algorithms. COPASI has been used to
model various aspects of virology, including mechanisms of
action [22, 88, 97, 103], pharmaceutical interventions [1], virus
life-cycle [4], vaccine design [39] and dynamics of epidemics [2,
124, 125]. COPASI has also been applied to COVID-19, particularly
to model the dynamics of the epidemic and effect of interven-
tions [116]. Some of the authors have also used COPASI to model
the local epidemics and forecast usage of hospital resources
(P. Mendes) and to compare the possible advantages of contact
network agent-based models over differential equation models
(S. Hoops).
COPASI is available from http://copasi.org/ and https://githu
b.com/copasi under the Artistic License 2.0.
COVIDSIM: epidemiological models of viral spread
Classical epidemiological models have seen broad reuse in
describing the COVID-19 outbreak. Deterministic or compart-
mental mathematical models assign individuals in a population
to different subgroups and describe their dynamic changes
using systems of differential equations. For SARS-CoV-2, the
SEIR model and extended versions thereof are frequently used.
The underlying model framework is not new at all, and related
models have been described already at the beginning of the 20th
century to model infectious diseases [43]. In brief, in the SEIR
or SEIRD-Model, individuals in a population are grouped into
Susceptible (S), Exposed (E), Infected (I), Recovered (R) and Deceased
(D) individuals. Initially, all individuals except for a small
number who are already infected are considered susceptible to
infection. The model can then simulate the population infection
dynamics, using parameters such as the incubation time or the
average disease duration for parameterization of the differential
equations. Such SEIR models have been used to predict the
COVID-19 dynamics, e.g. in Spain and Italy, and to analyse
the effect of control strategies [60]. Extended versions of the
SEIR model were developed to guide political decision-making
[44]. For example, in Germany, this model is implemented
in COVIDSIM, including hospitalized patients and patients in
intensive care and implementing effects of contact reduction
measures. It can be overlaid with data from different German
federal states and data from other countries. This model has a
convenient web interface (see Figure 7), permitting the user to
change model parameters and get an intuitive feeling for the
model dynamics – allowing it to estimate infection parameters
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Figure 7. Web interface of the COVIDSIM simulator. The interface is allowing the user to modify model parameters and compare simulated dynamics with real infection
data.
The web interface is available via http://www.kaderali.
org:3838/covidsim.
CoV-GLUE: tracking nucleotide changes
in the SARS-CoV-2 genome
SARS-CoV-2 is naturally accumulating nucleotide mutations in
its RNA genome as the pandemic progresses. Point mutations,
specifically non-synonymous substitutions, will result in amino
acid replacements in viral genome sequences, while other muta-
tions will result in insertions or deletions (indels). On average
the observed changes would be expected to have no or minimal
consequence for virus biology. However tracking these changes
will help us better understand and control the pandemic as
mutations could arise with impact on virus biology and could
lead to escape from antiviral drugs and future vaccines. The
purpose of CoV-GLUE is to track the changes accumulating in the
SARS-CoV-2 genome (see Figure 8). The resource was developed
exploiting GLUE, a data-centric bioinformatics environment for
virus sequence data, with a focus on variation, evolution and
sequence interpretation [90]. Sequences are downloaded from
GISAID EpiCoV [89] approximately every week and added to a
constrained alignment within the GLUE framework. Users can
browse the accumulating variation or submit a FASTA file of
a novel genome to CoV-GLUE for comparison to the available
data. An amino acid replacements, indels and diagnostic primer
design report is generated from the submitted data. The user can
access the detected variants and using a phylogenetic placement
maximum-likelihood method [94] visualize their sequence rela-
tive to a reference data set. The user’s sequence is also assigned
to a lineage consistent with [80].
CoV-GLUE will help advance SARS-CoV-2 research by
tracking changes accumulating in the SARS-CoV-2 genome. CoV-
GLUE web application is available online via http://cov-glue.
cvr.gla.ac.uk/. CoV-GLUE is not released as an open source
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Figure 8. List of amino acid replacements to the SARS-CoV-2 reference sequence. Replacements have been detected in GISAID SARS-CoV-2 sequences from the
pandemic using CoV-GLUE.
data (see Section Detection and annotation). The underlying
software system GLUE is open source and licensed under the
GNU Affero General Public License v3.0 (AGPLv3).
PoSeiDon: Positive Selection Detection and
Recombination Analysis
Viruses and their hosts are in constant competition, and selec-
tion pressure continuously affects the evolution of their genes.
Selection pressure, in the form of positive selection, can be stud-
ied by comparing the rates of non-synonymous (dN) and synony-
mous substitutions (dS) in an alignment of orthologous genes.
Over several sites (codons), the dN/dS ratio can reach values
well above 1 [121]. Such positively selected sites are described
in recent SARS-CoV-2 studies. For example, [109] showed that
the selection pressure on ORF3a and ORF8 genes can drive the
evolution of the virus during the COVID-19 pandemic, while
[47] describe worrying changes in the spike protein through the
detection of positive selection.
PoSeiDon simplifies the detection of positive selection in
protein-coding sequences [36]. Firstly, the pipeline builds a mul-
tiple sequence alignment, estimates a best-fitting substitution
model and performs a recombination analysis followed by the
construction of all corresponding phylogenies. Secondly, pos-
itively selected sites under varying models are detected. The
results are summarized in a user-friendly web page, providing all
intermediate results and graphically displaying recombination
events and positively selected sites.
The rapid detection of positive selection helps to monitor
protein changes of SARS-CoV-2 during the pandemic. It pro-
vides potential target sites for drug development, helping to
counteract the virus during its ”arms race” with the human
species.
Poseidon is available via GitHub under MIT License: https://
github.com/hoelzer/poseidon.
Drug design
To limit the pandemic threat, it is of utmost importance to
develop therapy and vaccination strategies against COVID-19.
Understanding the molecular mechanisms underlying the dis-
ease’s pathogenesis is key to identifying potential drug candi-
dates for clinical trials. Viral-host protein-protein interactions
(PPIs) play a crucial role during viral infection and hold promising
therapeutic prospects.
To facilitate the identification of potential drugs, a screening
of known drugs and PPIs, referred to as drug repurposing, is
usually cheaper and more time-efficient than designing drugs
from scratch [41, 86]. This is especially true for SARS-CoV-2,
as it is a member of a viral genus that has been thoroughly
studied. Therefore, we can infer information and potential drug
targets from other betacoronaviruses, and especially SARS-CoV-
1. The described databases contain information about virus-
host PPIs (see VirHostNet, CoVex) and virus-drug interactions
(see CORDITE, CoVex) and gather information from other viruses
and drugs to infer potential PPIs for SARS-CoV-2 (see CoVex,
P-HIPSTer).
VirHostNet SARS-CoV-2 release
The complete understanding of molecular interactions between
SARS-CoV-2 and host cellular proteins is key to highlight func-
tions that are essential for viral replication and pathogenesis
of COVID-19 outbreak. Toward this end, VirHostNet [30] was
upgraded in March 2020 to include a comprehensive collection
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literature involving ORFeomes from multiple coronaviruses,
including MERS-CoV, SARS-CoV-1 and SARS-CoV-2. This biocu-
ration effort also incorporated, in close to real-time, the data
obtained through affinity-purification mass spectrometry by
the Korgan laboratory [26]. Hence, in a few days, more than
650 binary protein-protein interactions were made available to
scientists working on COVID-19.
The VirHostNet resource was rapidly catalogued as a fair
and open data resource to help fight against COVID-19 [84].
To leverage the cost of highly expensive experiments, open
access is provided to the interology web application allowing fast
and reproducible in silico prediction of SARS-CoV-2/human inter-
actome The interactome predicted for SARS-CoV-2 was wired
to an anti-apoptotic switch regulated by Bcl-2 family mem-
bers that could potentially be a therapeutic target. The network
reconstruction identified the prosurvival protein Bcl-xL and the
autophagy effector Beclin 1 as vulnerable nodes in the host
cellular defense system against SARS-CoV-2. Interestingly, both
proteins harbour a so-called Bcl-2 homology 3 (BH3)-like motif,
which is involved in homotypic (inside the Bcl-2 family) and
heterotypic interactions with other domains.
The VirHostNet SARS-CoV-2 release will accelerate research
on the molecular mechanisms underlying virus replication as
well as COVID-19 pathogenesis and will provide a systems virol-
ogy framework for prioritizing drug candidates repurposing.
VirHostNet web application is available via http://virhostnet.
prabi.fr/. All data is open access.
CORDITE: CORona Drug InTERactions database
CORDITE collects data on potential drugs, targets and their
interactions for SARS-CoV-2 from published articles and
preprints [62]. CORDITE integrates many functionalities to
enable users to access, sort and download relevant data to
conduct meta-analyses, to design new clinical trials or even
to conduct a curated literature search. CORDITE automatically
incorporates publications from PubMed (https://www.ncbi.nlm.
nih.gov/pubmed/), bioRxiv (https://www.biorxiv.org/), chemRxiv
https://www.chemrxiv.org/) and medRxiv https://www.medrxi
v.org/) that report information on computational, in vitro, or
case studies on potential drugs for COVID-19. Besides original
research, reviews and comments are also included in the
database. The information from the articles and preprints
are manually curated by moderators and can be accessed via
the web server or the open API. Moreover, registered clinical
trials from the NIH https://clinicaltrials.gov/) for COVID-19
are also included. Users can directly access the publications,
interactions, drugs, targets and clinical trials, and thus the data
can be easily integrated into other software or apps.
The CORDITE database is updated weekly and, at the date of
submission, provides data for more than 700 interactions of 23
targets for more than 530 drugs from almost 300 publications
and more than 240 clinical trials (as of May 19, 2020). It is thus
the largest, curated database available for drug interactions for
SARS-CoV-2. It allows researchers to carry out meta-analyses
on potential drugs systematically and to identify potential drug
candidates for clinical trials.
CORDITE can be accessed via https://cordite.mathematik.u
ni-marburg.de (CC BY-ND).
CoVex: CoronaVirus Explorer
CoVex [83] is a network and systems medicine web platform
that integrates experimental virus-human protein interactions
for SARS-CoV-2 [26] and SARS-CoV-1 [30, 75], human protein-
protein interactions [49] and drug-protein interactions [24, 65,
106, 114, 117, 122] into a large-scale interactome (see Figure 9).
It allows biomedical and clinical researchers to predict novel
drug targets as well as drug repurposing candidates using several
state-of-the-art graph analysis methods specifically tailored to
the network medicine context. Here, expert knowledge about
virus replication, immune-related biological processes or drug
mechanisms can be applied to compile a set of host or viral
proteins (referred to as seeds). Alternatively, users can upload
a list of proteins (e.g. differentially expressed genes, a list of pro-
teins related to a molecular mechanism of interest) or proteins
targeted by drugs of interest (e.g. a set of drugs known to be
effective) as seeds to guide the analysis. Based on the selected
seeds, CoVex offers three main actions: (1) searching the human
interactome for viable drug targets, (2) identifying repurposable
drug candidates and (3) a combination of actions, i.e. starting
from a selection of virus or virus-interacting proteins, users can
mine the interactome for suitable drug targets for which, in
turn, suitable drugs are identified. In summary, CoVex allows
researchers to systematically identify already approved drugs
that could be repurposed to treat SARS-CoV-2, which is faster
than developing new drugs from scratch.
CoVex web application is available via https://exbio.wzw.tum.
de/covex/.
P-HIPSTer: a virus–host protein–protein interaction
resource
Viral-host protein-protein interactions (PPIs) play a crucial role
during viral infection by co-opting host cellular processes and
hold promising therapeutic prospects. Along these lines, the P-
HIPSTer database can significantly contribute to SARS-CoV2
research by providing: (1) testable hypotheses on molecular
interactions underlying viral infection and pathogenesis and (2)
highlighting host factors and pathways that serve as potential
drug targets to treat infection caused by different coronaviruses.
P-HIPSTer comprises ∼282,000 predicted viral-human PPIs on
∼1,000 viruses with an experimental validation rate of ∼76% [52].
Its predictive algorithm is an adaptation of PrePPI [21, 123] and
combines sequence and structural information to infer viral-
human PPIs mediated by domain-domain or peptide-domain
contacts (see Figure 10). In addition, P-HIPSTer builds all-atom
interaction models for high-confidence PPI predictions involving
folded domains and integrates sequence- and structure-based
functional annotations for viral proteins at multiple levels,
including host biological pathways based on the predicted
PPIs [3, 20, 23, 96]. Hence, P-HIPSTer constitutes a complimen-
tary resource to high-throughput experimental approaches
[26]. As of April 2020, P-HIPSTer contains predictions for 15
coronaviruses with varying pathogenic potential (alpha- and
betacoronaviruses) and reports 4,587 viral-host PPIs involving
397 human proteins. This unique collection of predicted viral-
human PPIs enables the discovery of PPIs commonly employed
within the Coronaviridae family and PPIs associated with their
pathogenicity.
The database is available via http://www.phipster.org/
Concluding remarks
Bioinformaticians around the world have reacted quickly to the
COVID-19 pandemic by providing coronavirus-specific tools to
advance SARS-CoV-2 research and boost the detection, under-
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Figure 9. CoVex: CoronaVirus Explorer.CoVex is a network medicine web platform that allows its users to interactively mine a large interactome that integrates
information about virus–host protein interactions, known human protein–protein interactions as well as drug–protein interactions. CoVex can be used for identifying
potential drug targets and drug repurposing candidates.
Figure 10. P-HIPSTer combines sequence and structural information to predict viral-host PPIs. P-HIPSTer evaluates the likelihood ratio (LR) for the potential interaction
between a viral protein (in red) and a human protein (in blue) combining three evidences: (i) domain–domain LR that two structure domains interact based on known
complex (green and purple domain–domain complex) comprised of their structural neighbours; (ii) peptide–domain LR that an unstructured peptide in one query
binds to a structured domain in the second query based on known binding motifs/peptide–domain complex (green and purple peptide–domain complex) using both
sequence and structural similarity; (iii) redundancy LR based on evidence that multiple structural neighbours (in orange, purple and green) of one query protein is
known to interact with the remaining query protein. Each viral protein is functionally annotated based on sequence and structural similarity (either using homology
models or known protein structures) and their corresponding set of predicted interacting human proteins.
to be complete, and in light of the rapid ongoing research, further
tools will be developed.
Efficient response to the pandemic requires high-quality
SARS-CoV-2 data and meta-data [87] and newly released
software to be available freely and as open source. Open
source code invites other developers to improve the software.
Preferably, code should be shared via a suitable repository such
as GitHub, allowing for transparency and managing versioning
and feature development. In particular, when software and
resources are evolving as fast as the virus, versioning and
reproducibility of all steps are of increasing importance. In
the context of pipelines, versions of third-party tools should be
fixed using package managers like Conda or by encapsulation
using container software (Docker [5], Singularity). Workflow
management systems such as SnakeMake or Nextflow [19, 100]
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platforms. In the best case, all tools and pipelines should be
automatically and continuously tested to evaluate their quality
and usability. Also, manuscripts on software and methods
development can be made available as preprints to accelerate
their dissemination. Of course, these standards are not specific
for coronavirus related research, but rather general points about
bioinformatics software.
One major bottleneck hindering high software standards is
the limited capacity of scientists to build versatile software,
rather than prototypes. This might be improved by merging
projects with similar or overlapping goals. However, this requires
a central overview of newly developed tools and ongoing
research projects and of how (future) products may fit together,
e.g. in the form of a processing pipeline. Unfortunately, the life
cycle of software in research is relatively short. Usually, scientific
funding does not include the continuous maintenance of tools
and pipelines so that developers are forced to move on to other
projects and research grants.
The European Virus Bioinformatics Center curates a list
of bioinformatics tools specifically for coronaviruses (http://e
vbc.uni-jena.de/tools/coronavirus-tools/), some of which were
presented in this review. Other initiatives are collecting relevant
datasets (COVID-19 Data Portal, https://www.covid19datapo
rtal.org/) or are supporting researchers by offering assistance
with SARS-CoV-2 genome sequencing (NFDI4Microbiota, https://
nfdi4microbiota.de/index.php/covid-19/). ELIXIR (https://elixi
r-europe.org/services/covid-19) provides a range of services to
study SARS-CoV-2, in particular, the European Galaxy server
for data-intensive research that provides access to scientific
tools and training materials to guide users through COVID-19
data analysis. In addition, it is an encouraging development
seeing researchers joining efforts in national and international
initiatives to combat the ongoing pandemic. For example,
researchers around the world are jointly reconstructing the
molecular processes of the virus-host interactions to develop
a COVID-19 Disease Map [74].
Key Points
• In light of the sheer amount of data, many funda-
mental questions in SARS-CoV-2 research can only be
tackled with the help of bioinformatic tools.
• Bioinformatic analysis of SARS-CoV-2 data has the
potential to track and trace SARS-CoV-2 sequence
evolution and identify potential drug targets.
• All tools are free to use and available online to rapidly
advance SARS-CoV-2 research.
Availability
All presented tools are free to use and available online,
either through web applications or public code repositories.
Licenses are given in Table 1. You can find a list of the pre-
sented tools and further tools on the EVBC website: http://
evbc.uni-jena.de/tools/coronavirus-tools/
Acknowledgments
M.H. appreciates the support of the Joachim Herz Foundation
by the add-on fellowship for interdisciplinary life science.
P.L. acknowledges funding from the EpiPose project (Euro-
pean Union’s SC1-PHE-CORONAVIRUS-2020 programme,
H2020/101003688). Á.N.O.T. thanks Anthony Underwood and
David Aanensen (Centre for Genomic Pathogen Surevillance,
Hinxton, Cambridgeshire), as well as JT McCrone and Verity
Hill (Rambaut Group, Edinburgh University) for contributions
to the pangolin code. G.R.-P. thanks the CABANA Project
for their support while conducting a research secondment
at EMBL-EBI. We acknowledge the UniProt Consortium
for the production of UniProt. GISAID acknowledgements




This work was supported by the Agencia Nacional de
Promoción Científica y Tecnológica [PICT 2016-1327 and
PICT 2017-2581 to M.C.]; the Biotechnology and Biolog-
ical Sciences Research Council [BB/N018354/1 to A.A.,
BB/S020462/1 to A.B., and BB/P027849/1 to A.R. and G.R.-P.];
the Bundesministerium für Bildung und Forschung [5103388
to J.B., 13GW0096D and 13GW0423B to C.B. and 031L0176A
to M.v.K.]; the Carl Zeiss Foundation [CZS 0563-2.8/738/2
to K.L.]; the Deutsche Forschungsgemeinschaft [FZT 118 to
F.H., CRC 1076 to M.H. and SPP 1596 to M.M.]; the European
Commission [H2020/777111 to S.S. and J.B., H2020/826078
to J.B. and ESF/14-BM-A55-0014/16 to L.K.,]; the European
Molecular Biology Laboratory core funds to M.J.M.; the
Fondation Innovations en Infectiologie [R12128CC to V.N.];
the Max Planck Society to D.K.; the Medical Research Council
[MC_UU_1201412 to D.L.R. and J.B.S.]; the National Institutes
of Health [GM080219 to S.H. and P.M., U24HG007822 to
M.J.M., C.A. and N.R., U19 AI142777-02 to G.L. and Intramural
Research Program of the National Library of Medicine to
E.P.N.]; the Swiss Federal Government through the State
Secretariat for Education, Research and Innovation to N.B.
and N.R; the Velux Foundations [13154 to J.B.]; and the
Wellcome Trust [203783/Z/16/Z to Á.N.O.T.].
References
1. Aguilera LU, Rodríguez-González J. Modeling the effect of
tat inhibitors on HIV latency. J Theor Biol 2019;473:20–7.
2. Akgül A, Khoshnaw SHA, Mohammed WH. Mathematical
model for the ebola virus disease. J Adv Phys 2018;7(2):190–8.
3. Bairoch A. The ENZYME database in 2000. Nucleic Acids Res
2000;28(1):304–5.
4. J. K. Barry. Mathematical modelling of the HIV life cycle:
identifying optimal treatment strategies. PhD thesis, Uni-
versity of Greifswald, 2018.
5. C. Boettiger. An introduction to docker for reproducible
research. ACM SIGOPS Operating Systems Review, 2015;
49(1):71–79.
6. Bouckaert R, Vaughan TG, Barido-Sottani J, et al. BEAST 2.5:
An advanced software platform for bayesian evolutionary
analysis. PLoS Comput Biol 2019;15(4):e1006650.
7. Breiman L. Random forests. Mach Learn 2001;45(1):5–32.
8. Brockmann D, Helbing D. The hidden geometry of
complex, network-driven contagion phenomena. Science
2013;342(6164):1337–42.
9. Brodie R, Smith AJ, Roper RL, et al. Base-by-base: Sin-
gle nucleotide-level analysis of whole viral genome align-







obert Koch-Institut user on 09 August 2021
Computational strategies to combat COVID-19 661
10. W. Chang, J. Cheng, J. Allaire, Y. Xie, and J. Mcpherson. shiny:
Web application framework for r. r package version 1.4.0.2.,
2020.
11. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel
coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveil-
lance 2020;25(3).
12. Cuypers L, Li G, Neumann-Haefelin C, et al. Mapping the
genomic diversity of HCV subtypes 1a and 1b: Implications
of structural and immunological constraints for vaccine
and drug development. Virus Evol 2016;2(2):vew024.
13. Cuypers L, Libin P, Schrooten Y, et al. Exploring resistance
pathways for first-generation NS3/4A protease inhibitors
boceprevir and telaprevir using Bayesian network learning.
Infect Genet Evol 2017;53:15–23.
14. De Maio N, Worby CJ, Wilson DJ, et al. Bayesian recon-
struction of transmission within outbreaks using genomic
variants. PLoS Comput Biol 2018;14(4):e1006117.
15. Eddy SR. Accelerated Profile HMM Searches. PLoS Comput
Biol 2011;7(10):e1002195.
16. Ehlers A, Osborne J, Slack S, et al. Poxvirus orthologous
clusters (POCs). Bioinformatics 2002;18(11):1544–5.
17. El-Gebali S, Mistry J, Bateman A, et al. The Pfam protein fam-
ilies database in 2019. Nucleic Acids Res 2018;47(D1):D427–32.
18. Elbe S, Buckland-Merrett G. Data, disease and diplomacy:
GISAID’s innovative contribution to global health. Global
Challenges 2017;1(1):33–46.
19. Ewels PA, Peltzer A, Fillinger S, et al. The nf-core frame-
work for community-curated bioinformatics pipelines. Nat
Biotechnol 2020;38:276–8.
20. Finn RD, Coggill P, Eberhardt RY, et al. The pfam pro-
tein families database: towards a more sustainable future.
Nucleic Acids Res 2015;44(D1):D279–85.
21. Garzón JI, Deng L, Murray D, et al. A computational interac-
tome and functional annotation for the human proteome.
eLife 2016;5:e18715.
22. Gebhard LG, Kaufman SB, Gamarnik AV. Novel ATP-
independent RNA annealing activity of the dengue virus
NS3 helicase. PLoS One 2012;7(4):e36244.
23. Gene Ontology Consortium. Expansion of the gene ontol-
ogy knowledgebase and resources. Nucleic Acids Res
2017;45(D1):D331, D338.
24. Gilson MK, Liu T, Baitaluk M, et al. BindingDB in 2015: A
public database for medicinal chemistry, computational
chemistry and systems pharmacology. Nucleic Acids Res
2015;44(D1):D1045–53.
25. Goebel SJ, Taylor J, Masters PS. The 3’ cis-acting genomic
replication element of the severe acute respiratory syn-
drome coronavirus can function in the murine coronavirus
genome. J. Virol. 2004;78(14):7846–51.
26. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 pro-
tein interaction map reveals targets for drug repurposing.
Nature 2020;583(7816):459–68.
27. Grenfell BT. Unifying the epidemiological and evolutionary
dynamics of pathogens. Science 2004;303(5656):327–32.
28. Grüning B, Dale R, Sjödin A, et al. Bioconda: sustainable and
comprehensive software distribution for the life sciences.
Nat Methods 2018;15(7):475–6.
29. Z. Gu, L. Gu, R. Eils, M. Schlesner, and B. Brors. circlize
implements and enhances circular visualization in R. Bioin-
formatics, 2014;30(19):2811–2812.
30. Guirimand T, Delmotte S, Navratil V. VirHostNet 2.0: surf-
ing on the web of virus/host molecular interactions data.
Nucleic Acids Res 2014;43(D1):D583–7.
31. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-
time tracking of pathogen evolution. Bioinformatics
2018;34(23):4121–3.
32. Hamming I, Timens W, Bulthuis M, et al. Tnumber distribu-
tion of ACE2 protein, the functional receptor for SARS coro-
navirus. a first step in understanding SARS pathogenesis. J
Pathol 2004;203(2):631–7.
33. Hillary W, Lin S-H, Upton C. Base-By-Base version 2: sin-
gle nucleotide-level analysis of whole viral genome align-
ments. Microb Inf Exp 2011;1(1):2.
34. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-
CoV-2 cell entry depends on ACE2 and TMPRSS2 and
is blocked by a clinically proven protease inhibitor. Cell
2020;181(2):271.e8–80.
35. M. Hoffmann, M. T. Monaghan, and K. Reinert. PriSeT:
Efficient De Novo primer discovery. bioRxiv, 2020.
36. Hölzer M, Marz M. PoSeiDon: a Nextflow pipeline for the
detection of evolutionary recombination events and posi-
tive selection. Bioinformatics 2020:btaa695.
37. Hoops S, Sahle S, Gauges R, et al. COPASI—a complex
pathway simulator. Bioinformatics 2006;22(24):3067–74.
38. Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogen-
esis, and control of COVID-19. Viruses 2020;12(4):372.
39. Kaliamurthi S, Selvaraj G, Kaushik AC, et al. Designing
of CD8+ and CD8+-overlapped CD4+ epitope vaccine by
targeting late and early proteins of human papillomavirus.
Biol: Targets Ther 2018;12:107.
40. Kalvari I, Argasinska J, Quinones-Olvera N, et al. Rfam 13.0:
shifting to a genome-centric resource for non-coding RNA
families. Nucleic Acids Res 2018;46(D1):D335–42.
41. Kapetanovic I. Computer-aided drug discovery and devel-
opment (CADDD): In silico-chemico-biological approach.
Chem. Biol. Interact. 2008;171(2):165–76.
42. Katoh K, Standley DM. MAFFT Multiple Sequence Align-
ment Software Version 7: Improvements in Performance
and Usability. Mol. Biol. Evol. 2013;30(4):772–80.
43. W. O. Kermack and A. G. McKendrick. A contribution
to the mathematical theory of epidemics. Proc R Soc A,
1927;115(772):700–721.
44. Khailaie S, Mitra T, Bandyopadhyay A, et al. Estimate of
the development of the epidemic reproduction number
rt from coronavirus SARS-CoV-2 case data and implica-
tions for political measures based on prognostics. medRxiv,
2020.
45. Kühnert D, Stadler T, Vaughan TG, et al. Phylodynamics
with migration: A computational framework to quantify
population structure from genomic data. Mol Biol Evol
2016;33(8):2102–16.
46. Klenk H-D, Garten W. Host cell proteases controlling virus
pathogenicity. Trends Microbiol. 1994;2(2):39–43.
47. Korber B, Fischer W, Gnanakaran S, et al. Spike mutation
pipeline reveals the emergence of a more transmissible
form of SARS-CoV-2. bioRxiv, 2020.
48. Köster J, Rahmann S. Snakemake—a scalable bioinformat-
ics workflow engine. Bioinformatics 2012;28(19):2520–2.
49. Kotlyar M, Pastrello C, Malik Z, et al. IID 2018 update:
context-specific physical protein–protein interactions in
human, model organisms and domesticated species.
Nucleic Acids Res 2018;47(D1):D581–9.
50. D. Kühnert, T. Stadler, T. G. Vaughan, and A. J. Drummond.
Simultaneous reconstruction of evolutionary history and
epidemiological dynamics from viral sequences with the







obert Koch-Institut user on 09 August 2021
662 F. Hufsky et al.
51. Kumar N, Sharma S, Barua S, et al. Virological and
immunological outcomes of coinfections. Clin Microbiol Rev
2018;31(4).
52. Lasso G, Mayer SV, Winkelmann ER, et al. A structure-
informed atlas of human-virus interactions. Cell 2019;
178(6):1526–41. e16.
53. Li D, Liu C-M, Luo R, et al. MEGAHIT: an ultra-fast
single-node solution for large and complex metagenomics
assembly via succinct de bruijn graph. Bioinformatics 2015;
31(10):1674–6.
54. Li H, Durbin R. Fast and accurate short read align-
ment with Burrows-Wheeler transform. Bioinformatics
2009;25(14):1754–60.
55. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting
enzyme 2 is a functional receptor for the SARS coronavirus.
Nature 2003;426(6965):450–4.
56. Libin P, Beheydt G, Deforche K, et al. RegaDB: community-
driven data management and analysis for infectious dis-
eases. Bioinformatics 2013;29(11):1477–80.
57. Libin P, Eynden EV, Incardona F, et al. PhyloGeoTool: inter-
actively exploring large phylogenies in an epidemiological
context. Bioinformatics 2017;33(24):3993–5.
58. Libin PJK, Deforche K, Abecasis AB, et al. VIRULIGN: fast
codon-correct alignment and annotation of viral genomes.
Bioinformatics 2019;35(10):1763–5.
59. Lin D, Liu L, Zhang M, et al. Co-infections of SARS-CoV-2
with multiple common respiratory pathogens in infected
patients. Sci China Life Sci 2020;63(4):606–9.
60. Lopez LR, Rodo X. A modified SEIR model to predict the
COVID-19 outbreak in spain and italy: simulating control
scenarios and multi-scale epidemics. medRxiv, 2020.
61. Madhugiri R, Karl N, Petersen D, et al. Structural and func-
tional conservation of cis-acting RNA elements in coron-
avirus 5’-terminal genome regions. Virology 2018;517:44–55.
62. Martin R, Löchel HF, Welzel M, et al. CORDITE: The
curated CORona Drug InTEractions database for SARS-CoV-
2. iScience 2020;23(7):101297.
63. Masters PS. Coronavirus genomic RNA packaging. Virology
2019;537:198–207.
64. McKenna A, Hanna M, Banks E, et al. The genome
analysis toolkit: a mapreduce framework for analyzing
next-generation DNA sequencing data. Genome Res 2010;
20(9):1297–303.
65. Mendez D, Gaulton A, Bento AP, et al. ChEMBL: towards
direct deposition of bioassay data. Nucleic Acids Res
2018;47(D1):D930–40.
66. Millet JK, Whittaker GR. Host cell proteases: Critical deter-
minants of coronavirus tropism and pathogenesis. Virus Res
2015;202:120–34.
67. Minh BQ, Nguyen MAT, von Haeseler A. Ultrafast
approximation for phylogenetic bootstrap. Mol Biol Evol
2013;30(5):1188–95.
68. Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: New
models and efficient methods for phylogenetic inference
in the genomic era. Mol Biol Evol 2020;37(5):1530–4.
69. Mitchell AL, Almeida A, Beracochea M, et al. MGnify: the
microbiome analysis resource in 2020. Nucleic Acids Res
2020;48(D1):D570–78.
70. Moore SC, Randal RP, Alruwaili M, et al. Amplicon based
MinION sequencing of SARS-CoV-2 and metagenomic char-
acterisation of nasopharyngeal swabs from patients with
COVID-19. medRxiv, 2020.
71. Nawrocki EP, Eddy SR. Infernal 1.1: 100-fold faster RNA
homology searches. Bioinformatics 2013;29(22):2933–5.
72. Ngcapu S, Theys K, Libin P, et al. Characterization of nucle-
oside reverse transcriptase inhibitor-associated mutations
in the RNase H region of HIV-1 subtype C infected individ-
uals. Viruses 2017;9(11).
73. O’Leary NA, Wright MW, Brister JR, et al. Reference
sequence (refseq) database at ncbi: current status, taxo-
nomic expansion, and functional annotation. Nucleic Acids
Res 2016;44:D733–45.
74. Ostaszewski M, Mazein A, Gillespie ME, et al. COVID-
19 disease map, building a computational repository of
SARS-CoV-2 virus-host interaction mechanisms. Sci Data
2020;7(1):136.
75. Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-
host interactome: Identification of cyclophilins as tar-
get for pan-coronavirus inhibitors. PLoS Pathog 2011;7(10):
e1002331.
76. Pineda-Peña A-C, Pingarilho M, Li G, et al. Drivers
of HIV-1 transmission: The portuguese case. PLoS One
2019;14(9):e0218226.
77. Posada-Céspedes S, Seifert D, Topolsky I, et al. V-pipe: a
computational pipeline for assessing viral genetic diversity
from high-throughput sequencing data. bioRxiv, 2020.
78. J. Quick. nCoV-2019 sequencing protocol v1 (protocols.io.
bbmuik6w). 2020.
79. Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR
method for MinION and Illumina sequencing of Zika and
other virus genomes directly from clinical samples. Nat
Protoc 2017;12(6):1261–76.
80. Rambaut A, Holmes EC, O’Toole Á, et al. A dynamic nomen-
clature proposal for SARS-CoV-2 lineages to assist genomic
epidemiology. Nat Microbiol 2020.
81. S. Rampelli, E. Biagi, S. Turroni, and M. Candela. Retrospective
search for SARS-CoV-2 in human faecal metagenomes. SSRN
Electronic J, 2020.
82. Reimering S, Muñoz S, McHardy AC. Phylogeographic
reconstruction using air transportation data and its appli-
cation to the 2009 H1N1 influenza A pandemic. PLoS Comput
Biol 2020;16(2):e1007101.
83. Sadegh S, Matschinske J, Blumenthal DB, et al. Exploring the
SARS-CoV-2 virus-host-drug interactome for drug repur-
posing. Nat Commun 2020;11(1):3518.
84. S.-A. Sansone, P. McQuilton, P. Rocca-Serra, A. Gonzalez-
Beltran, M. Izzo, A. L. Lister, and M. Thurston.
FAIRsharing as a community approach to standards,
repositories and policies. Nat Biotechnol 2019;37(4):
358–367.
85. Schäffer AA, Hatcher EL, Yankie L, et al. VADR: validation
and annotation of virus sequence submissions to GenBank.
BMC Bioinformatics 2020;21(1):211.
86. Schneider G, Fechner U. Computer-based de novo design
of drug-like molecules. Nat. Rev. Drug Discovery 2005;4(8):
649–63.
87. Schriml LM, Chuvochina M, Davies N, et al. COVID-19 pan-
demic reveals the peril of ignoring metadata standards. Sci
Data 2020;7(1):188.
88. Sheppard S, Dikicioglu D. Dynamic modelling of the killing
mechanism of action by virus-infected yeasts. J R Soc Inter-
face 2019;16(152):20190064.
89. Shu Y, McCauley J. GISAID: Global initiative on sharing
all influenza data—from vision to reality. Eurosurveillance
2017;22(13):30494.
90. Singer JB, Thomson EC, McLauchlan J, et al. GLUE: a flex-








obert Koch-Institut user on 09 August 2021
Computational strategies to combat COVID-19 663
91. Sola I, Mateos-Gomez PA, Almazan F, et al. RNA-RNA and
RNA-protein interactions in coronavirus replication and
transcription. RNA Biology 2011;8(2):237–48.
92. Solis-Reyes S, Avino M, Poon A, et al. An open-source k-mer
based machine learning tool for fast and accurate subtyp-
ing of HIV-1 genomes. PLoS One 2018;13(11):e0206409.
93. Stadler T, Kuhnert D, Bonhoeffer S, et al. Birth-death sky-
line plot reveals temporal changes of epidemic spread in
HIV and hepatitis c virus (HCV). Proc Natl Acad Sci U S A
2013;110(1):228–33.
94. Stamatakis A. RAxML version 8: a tool for phylogenetic
analysis and post-analysis of large phylogenies. Bioinfor-
matics 2014;30(9):1312–3.
95. Steinhauer DA. Role of Hemagglutinin Cleavage for the
Pathogenicity of Influenza Virus. Virology 1999;258(1):1–20.
96. Subramanian A, Tamayo P, Mootha VK, et al. Gene set
enrichment analysis: A knowledge-based approach for
interpreting genome-wide expression profiles. Proc Natl
Acad Sci U S A 2005;102(43):15545–50.
97. Tapia F, Laske T, Wasik MA, et al. Production of defective
interfering particles of influenza A virus in parallel contin-
uous cultures at two residence times–insights from qPCR
measurements and viral dynamics modeling. Front Bioeng
Biotechnol 2019;7:275.
98. Tcherepanov V, Ehlers A, Upton C. Genome annotation
transfer utility (GATU): rapid annotation of viral genomes
using a closely related reference genome. BMC Genomics
2006;7(1):150.
99. Theys K, Libin P, Dallmeier K, et al. Zika genomics urgently
need standardized and curated reference sequences. PLoS
Pathog 2017;13(9):e1006528.
100. Tommaso PD, Chatzou M, Floden EW, et al. Nextflow
enables reproducible computational workflows. Nat
Biotechnol 2017;35(4):316–9.
101. Torneri A, Libin P, Vanderlocht J, et al. A prospect on the use
of antiviral drugs to control local outbreaks of COVID-19.
BMC Med 2020;18:191.
102. Tu S-L, Staheli J, McClay C, et al. Base-by-base version 3:
New comparative tools for large virus genomes. Viruses
2018;10(11):637.
103. Tunnicliffe RB, Hautbergue GM, Wilson SA, et al. Compet-
itive and cooperative interactions mediate RNA transfer
from herpesvirus saimiri ORF57 to the mammalian export
adaptor ALYREF. PLoS Pathog 2014;10(2):e1003907.
104. UniProt Consortium. UniProt: a worldwide hub of protein
knowledge. Nucleic Acids Res 2019;47(D1):D506–15.
105. Upton C, Hogg D, Perrin D, et al. Viral genome organizer:
a system for analyzing complete viral genomes. Virus Res
2000;70(1-2):55–64.
106. Ursu O, Holmes J, Bologa CG, et al. DrugCentral 2018: an
update. Nucleic Acids Res 2018;47(D1):D963–70.
107. Vaughan TG, Leventhal GE, Rasmussen DA, et al. Estimating
epidemic incidence and prevalence from genomic data. Mol
Biol Evol 2019;36(8):1804–16.
108. Vaughan TG, Welch D, Drummond AJ, et al. Inferring ances-
tral recombination graphs from bacterial genomic data.
Genetics 2017;205(2):857–70.
109. Velazquez-Salinas L, Zarate S, Eberl S, et al. Positive selec-
tion of ORF3a and ORF8 genes drives the evolution of
SARS-CoV-2 during the 2020 COVID-19 pandemic. bioRxiv,
2020.
110. Volz EM, Pond SLK, Ward MJ, et al. Phylodynamics
of infectious disease epidemics. Genetics 2009;183(4):
1421–30.
111. Volz EM, Siveroni I. Bayesian phylodynamic inference with
complex models. PLoS Comput Biol 2018;14(11):e1006546.
112. Walls AC, Park Y-J, Tortorici MA, et al. Structure, Function,
and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell
2020;181(2):281–92. e6.
113. Waner JL. Mixed viral infections: detection and manage-
ment. Clin Microbiol Rev 1994;7(2):143–51.
114. Wang Y, Zhang S, Li F, et al. Therapeutic target database
2020: enriched resource for facilitating research and early
development of targeted therapeutics. Nucleic Acids Res
2020;48(D1):D1031–41.
115. Watkins X, Garcia LJ, Pundir S, et al. ProtVista: visu-
alization of protein sequence annotations. Bioinformatics
2017;33(13):2040–1.
116. Westerhoff HV, Kolodkin AN. Advice from a systems-
biology model of the corona epidemics. NPJ Syst. Biol. Appl
2020;6(1).
117. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a
major update to the DrugBank database for 2018. Nucleic
Acids Res 2017;46(D1):D1074–82.
118. Wright MN, Ziegler A. ranger: A fast implementation of
random forests for high dimensional data in C++ and R.
J Stat Softw 2017;77(1):1–17.
119. Wu F, Zhao S, Yu B, et al. A new coronavirus associ-
ated with human respiratory disease in China. Nature
2020;579(7798):265–9.
120. Yang D, Leibowitz JL. The structure and functions of
coronavirus genomic 3’ and 5’ ends. Virus Res. 2015;206:
120–33.
121. Yang Z. PAML 4: phylogenetic analysis by maximum likeli-
hood. Mol Biol Evol 2007;24(8):1586–91.
122. Young DA, DeQuach JA, Christman KL. Human cardiomyo-
genesis and the need for systems biology analysis. Wiley
Interdiscip Rev Syst Biol Med 2010;3(6):666–80.
123. Zhang QC, Petrey D, Deng L, et al. Structure-based prediction
of protein–protein interactions on a genome-wide scale.
Nature 2012;490(7421):556–60.
124. Zimmer C, Leuba SI, Cohen T, et al. Accurate quantifica-
tion of uncertainty in epidemic parameter estimates and
predictions using stochastic compartmental models. Stat
Methods Med Res 2018;28(12):3591–608.
125. Zimmer C, Yaesoubi R, Cohen T. A likelihood approach
for real-time calibration of stochastic compartmental epi-







obert Koch-Institut user on 09 August 2021
